Ascierto PA, Tang H, Dolfi S, Nyakas M, Marie Svane I, Muñoz-Couselo E, Grob JJ, Gomez-Roca CA, Chiarion-Sileni V, Peltola K, Larkin J, Melero I, Callahan M, Dummer R, Djidel P, Warad D, Reusser-Wolf D, Lipson EJ, Garnett-Benson C(2025) Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020 J Immunother Cancer, 13(2) DOI 10.1136/jitc-2024-009773, PubMed 40010775
Dajani O, Philips I, Størkson EK, Balstad TR, Brown LR, Bye A, Dolan R, Greil C, Hjermstad M, Jakobsen G, Kaasa S, McDonald J, Ottestad I, Sayers J, Simpson M, Sousa MS, Vagnildhaug OM, Yule MS, Laird BJA, Skipworth RJE, Solheim TS, Stares M, Arends J, Cancer Cachexia Endpoints Working Group(2025) Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series J Cachexia Sarcopenia Muscle, 16(2), e13756 DOI 10.1002/jcsm.13756, PubMed 40065459
Ghadimi M, Pelzer U, Besselink MG, Siveke J, Telgmann R, Braren R, Wilmink H, Crede M, Koenig A, Koenig U, Liffers ST, Antweiler K, Uijterwijk B, Seppanen H, Nordin A, Puolakkainen P, Dajani OF, Labori KJ, Johansson M, Bratlie SO, Friede T, Jo P(2025) Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial BMC Cancer, 25(1), 208 DOI 10.1186/s12885-025-13573-7, PubMed 39915735
